# Effect of an L-carnitine-containing Peritoneal Dialysis (PD) Solution on Insulin Sensitivity in Patients on Continuous Ambulatory Peritoneal Dialysis (CAPD)

> **NCT00755456** · PHASE2 · COMPLETED · sponsor: **Iperboreal Pharma Srl** · enrollment: 35 (actual)

## Conditions studied

- End Stage Renal Disease
- Insulin Resistance

## Interventions

- **DRUG:** PD solution containing glucose
- **DRUG:** PD solution containing glucose and L-carnitine

## Key facts

- **NCT ID:** NCT00755456
- **Lead sponsor:** Iperboreal Pharma Srl
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2012-09
- **Final completion:** 2012-10
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2019-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00755456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00755456, "Effect of an L-carnitine-containing Peritoneal Dialysis (PD) Solution on Insulin Sensitivity in Patients on Continuous Ambulatory Peritoneal Dialysis (CAPD)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00755456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*